Interestingly, PI3K activation in KRAS-mutant lung and colon cells is dependent on insulin-like growth factor 1 receptor (IGF1R) activity and a combination of MEK and IGF1R inhibitors showed synergistic effects both in NSCLC and colorectal cancer (CRC) [58,59]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.